You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – GlaxoSmithKline said Monday that the supplemental new drug application for niraparib (Zejula) as a first-line maintenance treatment for chemotherapy-responsive advanced ovarian cancer was accepted by the US Food and Drug Administration.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.